# Cellmeat: Research, Seoul, South Korea

> Cellmeat: CellMEAT is a South Korean biotechnology and food technology company that focuses on cultured meat production using cell-based techniques.

Source: https://millionrounds.com/startup/cellmeat (Millionrounds; every figure on the page links to its filing or article)

South Korea · [Research startup](https://millionrounds.com/companies)

# Cellmeat

CellMEAT is a South Korean biotechnology and food technology company that focuses on cultured meat production using cell-based techniques.

Funding reported Last round: Series A

Research Seoul, South Korea

Company summary

- **Founded:** 2019 7 years old
- **Team:** 5 1 to 10 people
- **Funding reported:** 32.8B as listed, currency not stated
- **Last round:** Series A May 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Cellmeat has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Cellmeat

CellMEAT is a South Korean biotechnology and food technology company that focuses on cultured meat production using cell-based techniques.

Founded in 2019 and headquartered in Gwangju, with operations in Seoul, the company aims to provide sustainable protein alternatives through cellular agriculture. CellMEAT has raised $33.6 million in funding and employs around 25 people, generating approximately $10.5 million in annual revenue. The company's primary product line, "GogiMEAT," includes cultured seafood and meat products, such as shrimp and caviar. A notable innovation is their proprietary CSF-A1, a fetal bovine serum-free cell culture medium that enhances cell growth efficiency. CellMEAT also utilizes non-animal serum-free cell culture technology and mass cell culture technology to support economic viability and scalability in production. They operate a mass production center in Seoul, furthering their commitment to sustainable food production.

## What company datasets say Cellmeat raised

Funding, as reported

Reported in all **32.8B** in the source's currency

Rounds **4**

Last round **Series A**

Last round size **4.9M**

Last round date **May 2023**

Investors listed **13**

## On a portfolio page

Investors who name them

- [Genting Ventures](https://millionrounds.com/fund/genting-ventures)

Each firm lists Cellmeat on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

biotechnology research b2c

Built with from their website

Google Workspace Google Meet Nginx Gmail

- **Sector:** Research
- **Industry code:** NAICS 541714, 311999, SIC 2836, 2011
- **Region:** Seoul
- **Revenue:** 2M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/cellmeat)

## Research in South Korea

Startups like it

- [**Galux** founded 2020 *Raised*](https://millionrounds.com/company/galux)
- [**ExoCoBio** founded 2017 *Raised*](https://millionrounds.com/company/exocobio)
- [**iN Therapeutics** Yongin-si · founded 2020](https://millionrounds.com/startup/in-therapeutics)
- [**Mitoimmune Therapeutics Inc.** Seoul · founded 2018](https://millionrounds.com/startup/mitoimmune-therapeutics-inc)
- [**Cyrus Therapeutics** founded 2019](https://millionrounds.com/startup/cyrus-therapeutics)
- [**G+FLAS Life Sciences, Inc.** Seoul · founded 2014](https://millionrounds.com/startup/g-flas-life-sciences-inc)
- [**Dx & Vx** founded 2001](https://millionrounds.com/startup/dx-vx)
- [**Bertis Inc** Seongnam-si · founded 2014](https://millionrounds.com/startup/bertis-inc)

## Is this your company?

Add your raise, your deck and your story, and put Cellmeat in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)